EVAX — Evaxion Biotech A/S Share Price
0.000.00%
Last trade - 00:00- $10.61m
- $15.90m
- $0.07m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | n/a | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 86.8 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -347.96% | ||
| Return on Equity | -822.05% | ||
| Operating Margin | -16289.52% | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | n/a | n/a | n/a | 0.07 | 0.16 | 0.13 | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Evaxion Biotech A/S is a Denmark-based clinical-stage biotechnology company, which specializes in the development of AI-driven immunotherapies to improve the lives of patients with cancer and infectious diseases. The Company decodes the human immune system to discover and develop immunotherapies to treat cancer and infectious diseases. Based on AI-immunology core technology, Evaxion is developing a pipeline of product candidates. In addition, Evaxion develops portfolio of vaccines to prevent bacterial and viral infections.
Directors
- Last Annual
- December 31st, 2023
- Last Interim
- March 31st, 2024
- Incorporated
- August 11th, 2008
- Public Since
- February 5th, 2021
- No. of Employees
- 49
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- NASDAQ Capital Market
- Shares in Issue
- 37,897,780
- Address
- Bredgade 34E, Copenhagen K, COPENHAGEN, 1260
- Web
- https://www.evaxion-biotech.com/
- Phone
- Auditors
- EY Godkendt Revisionspartnerselskab
Upcoming Events for EVAX
Q2 2024 Evaxion Biotech A/S Earnings Release
Q3 2024 Evaxion Biotech A/S Earnings Release
Similar to EVAX
180 Life Sciences
NASDAQ Capital Market
Abeona Therapeutics
NASDAQ Capital Market
ABVC Biopharma
NASDAQ Capital Market
Acesis Holdings
NASDAQ Capital Market
Achieve Life Sciences
NASDAQ Capital Market
FAQ
What is the Evaxion Biotech A/S share price?
As of Today at 20:33 UTC, shares in Evaxion Biotech A/S are trading at $2.84. This share price information is delayed by 15 minutes.
How has the Evaxion Biotech A/S share price performed this year?
Shares in Evaxion Biotech A/S last closed at $2.84 and the price had moved by +129.03% over the past 365 days. In terms of relative price strength the Evaxion Biotech A/S share price has outperformed the S&P500 Index by +82.25% over the past year.
What are the analyst and broker recommendations for Evaxion Biotech A/S?
The overall consensus recommendation for Evaxion Biotech A/S is Buy. You can view the full broker recommendation list by unlocking its StockReport.
What is the Evaxion Biotech A/S dividend yield?
Evaxion Biotech A/S does not currently pay a dividend.
Does Evaxion Biotech A/S pay a dividend?
Evaxion Biotech A/S does not currently pay a dividend.
When does Evaxion Biotech A/S next pay dividends?
Evaxion Biotech A/S does not currently pay a dividend.
How do I buy Evaxion Biotech A/S shares?
To buy shares in Evaxion Biotech A/S you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Evaxion Biotech A/S?
As of the previous close price of $2.84, shares in Evaxion Biotech A/S had a market capitalisation of $10.76m.
Where are Evaxion Biotech A/S shares listed?
Here are the trading details for Evaxion Biotech A/S:
- Country of listing: United States
- Exchange: NAQ
- Ticker Symbol: EVAX
What kind of share is Evaxion Biotech A/S?
Based on an overall assessment of its quality, value and momentum Evaxion Biotech A/S is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Evaxion Biotech A/S share price forecast for 2024?
The analyst consensus target price for shares in Evaxion Biotech A/S is $11.75. That is 313.73% above the last closing price of $2.84.
Analysts covering Evaxion Biotech A/S currently have a consensus Earnings Per Share (EPS) forecast of -$1.75 for the next financial year.
What is the trend in the Evaxion Biotech A/S share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Evaxion Biotech A/S. Over the past six months, its share price has outperformed the S&P500 Index by +249.5%.
As of the last closing price of $2.84, shares in Evaxion Biotech A/S were trading +15.79% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Evaxion Biotech A/S PE Ratio?
The Evaxion Biotech A/S PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $2.84.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Evaxion Biotech A/S?
We do not have data on Evaxion Biotech A/S' directors